The DOI matches its Crossref record; 171 of the 179 references it cites were found in a registry or an index.
The Rb/E2F pathway: expanding roles and emerging paradigms
Open accessAbstract
The retinoblastoma gene was identified over a decade ago as the first tumor suppressor. Although the gene was initially cloned as a result of its frequent mutation in the rare pediatric eye tumor, retinoblastoma (Friend et al. 1986; Fung et al. 1987; Lee et al. 1987), it is now thought to play a fundamental role in cellular regulation and is the target of tumorigenic mutations in many cell types. The retinoblastoma gene encodes a 928–amino acid phosphoprotein, Rb, which arrests cells in the G1 phase (Weinberg 1995). Rb is phosphorylated and dephosphorylated during the cell cycle; the hyperphosphorylated (inactive) form predominates in proliferating cells, whereas the hypophosphorylated (active) form is generally more abundant in quiescent or differentiating cells (Chen et al. 1989). As a demonstration its tumor suppressor activity, Rb was reintroduced into Rb-deficient tumor cells and it blocked several features of the malignant phenotype (Huang et al. 1988). Mutations affecting the retinoblastoma gene are frequently encountered, not only in retinoblastoma but also in other cancers such as osteosarcoma, small cell lung cancer, prostate cancer, and breast cancer (Friend et al. 1986; Fung et al. 1987; Harbour et al. 1988; Lee et al. 1988; T’Ang et al. 1988; Bookstein et al. 1990). Indeed, children with hereditary retinoblastoma have 30-fold increased risk of developing a second, nonocular malignancy, especially bone and soft tissue sarcomas in adolescence and cutaneous melanomas in adulthood (Eng et al. 1993; Moll et al. 1997). These second neoplasms occur almost exclusively in patients who have germ-line mutations in the retinoblastoma gene. As a further indication of its fundamental role in tumor suppression, Rb can be functionally inactivated by constitutive hyperphosphorylation in tumors that do not have mutations in the retinoblastoma gene (Sherr 1996). In addition, DNA tumor viruses express oncoproteins, such as adenovirus E1A, SV40 large tumor antigen, and human papillomavirus (HPV) E7, that bind and inactivate Rb; these proteins are required for the viruses to transform cells (DeCaprio et al. 1988; Whyte et al. 1988; Dyson et al. 1989). Rb function depends, at least in part, on interactions with the E2F family of DNA-binding transcription factors (E2F) (Chellappan et al. 1991; Dyson 1998; Nevins 1998). E2F sites are found in the promoters of many genes that are important for cell cycle progression, and Rb appears to repress transcription of these genes through its interaction with E2F (Blake and Azizkhan 1989; Thalmeier et al. 1989; Dalton 1992; Ohtani et al. 1995). Recent findings in the Rb/E2F field are clarifying how this pathway regulates the transition from G1 to S phase at the molecular level. Other emerging results show that this pathway also regulates other parts of the cell cycle and that it may even have roles beyond cell cycle control. In this article, we review the current understanding of the mechanism of action of Rb and its roles in cell cycle regulation, apoptosis, and development. We refer readers to recent reviews by Bartek et al. (1997), Dyson (1998), Lipinski and Jacks (1999), and Sherr and Roberts (1999) for additional in-depth analysis of the field and for historical perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cell cycle progresses normally when RB is inactivated by phosphorylation facilitated by different cyclin–CDK complexes67.”
From Molecular regulation of stem cell quiescence (2013) · cites this paper as [67]
In the citing paper
“The growth suppressive properties of Rb are largely, but not completely, associated with its binding to the transcription factor E2F and repressing transcription at target promoters (Classon and Harlow, 2002; Harbour and Dean, 2000; Stevaux and Dyson, 2002).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Harbour and Dean, 2000
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“MDM2 interacts with the p53 tumor suppressor protein and opposes its proapoptotic activity by repressing p53 transcriptional activation and by mediating its degradation (Haupt et al. 1997; Kubbutat et al. 1997).”
BackgroundThe human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017 · cited 3×
“In addition, DNA tumor viruses express oncoproteins, such as adenovirus E1A, SV40 large tumor antigen, and human papillomavirus (HPV) E7, that bind and inactivate Rb; these proteins are required for the viruses to transform cells (DeCaprio et al. 1988; Whyte et al. 1988; Dyson et al. 1989).”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome
Kornberg, R. D., & Lorch, Y. (1999) · Cell · doi:10.1016/s0092-8674(00)81958-3 · Cited by 1,833
Flagged first, then by citations
8 of the 179 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 3,417
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Zhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,639
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,558
Metadata
- Authors
- Harbour, J. W., & Dean, D. C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Dean, Douglas C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-10-01
- Volume
- 14
- Issue
- 19
- Pages
- 2393-2409
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2152616419
- Cited by
- 1,153
- References
- 179
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 25 · 2023: 25 · 2022: 15 · 2021: 37 · 2020: 28 · 2019: 23 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 41 · 2014: 42 · 2013: 46 · 2012: 40
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- retinoblastoma protein, Rb/E2F pathway, E2F transcription factors, tumor suppressor, G1 cell cycle arrest, retinoblastoma protein phosphorylation, second primary malignancy, hereditary retinoblastoma, cell cycle regulation, cell proliferation, cell differentiation, cell death, cell adhesion, adhesion molecules
- MeSH terms
- Carrier Proteins, Cell Cycle, DNA-Binding Proteins, Gene Expression Regulation, Models, Biological, Morphogenesis, Transcription Factors, Retinoblastoma Protein, Genes, Retinoblastoma, Cell Cycle Proteins, E2F Transcription Factors, Retinoblastoma-Binding Protein 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review